Compare EVTV & SKYE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | EVTV | SKYE |
|---|---|---|
| Founded | 2012 | 2012 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Auto Manufacturing | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 21.6M | 24.2M |
| IPO Year | 2014 | 2013 |
| Metric | EVTV | SKYE |
|---|---|---|
| Price | $2.18 | $0.81 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 3 |
| Target Price | N/A | ★ $15.00 |
| AVG Volume (30 Days) | ★ 374.5K | 202.9K |
| Earning Date | 04-13-2026 | 05-08-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $5,939,008.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 217.58 | N/A |
| 52 Week Low | $0.15 | $0.57 |
| 52 Week High | $5.07 | $5.75 |
| Indicator | EVTV | SKYE |
|---|---|---|
| Relative Strength Index (RSI) | 67.45 | 48.62 |
| Support Level | $1.94 | $0.71 |
| Resistance Level | $2.19 | $0.83 |
| Average True Range (ATR) | 0.14 | 0.09 |
| MACD | 0.04 | -0.01 |
| Stochastic Oscillator | 84.06 | 18.81 |
Envirotech Vehicles Inc is a provider of purpose-built zero-emission electric vehicles focused on reducing the total cost of vehicle ownership and helping fleet operators unlock the benefits of green technology. It recognizes revenue from the sales of zero-emission electric vehicles and vehicle maintenance and inspection services. The Company serves commercial and last-mile fleets, school districts, public and private transportation service companies and colleges and universities to meet the increasing demand for light to heavy-duty electric vehicles.
Skye Bioscience Inc is a pre-clinical pharmaceutical company located in San Diego, California. The company's clinical assets focus on the modulation of cannabinoid receptor 1 ("CB1") to provide novel treatments and alternatives for diseases caused by metabolic disorders, inflammation, fibrosis, and neurodegeneration, such as obesity and glaucoma. The company's Phase 2 clinical candidates include nimacimab, a negative allosteric modulating antibody that inhibits peripheral CB1 receptors, currently being developed for the treatment of obesity and SBI-100 Ophthalmic Emulsion ("SBI-100 OE"), a CB1 agonist (activator), currently being developed for the treatment of glaucoma and ocular hypertension.